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Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited
cardiac muscle disease with left ventricular hypertrophy, interstitial fibrosis and diastolic
dysfunction. Increased myofilament Ca2+ sensitivity could be the underlying cause of
diastolic dysfunction. Epigallocatechin-3-gallate (EGCg), a catechin found in green tea,
has been reported to decreasemyofilament Ca2+ sensitivity in HCMmodels with troponin
mutations. However, whether this is also the case for HCM-associated thick filament
mutations is not known. Therefore, we evaluated whether EGCg affects the behavior of
cardiomyocytes and myofilaments of an HCM mouse model carrying a gene mutation
in cardiac myosin-binding protein C and exhibiting both increased myofilament Ca2+
sensitivity and diastolic dysfunction.
Methods and Results: Acute effects of EGCg were tested on fractional sarcomere
shortening and Ca2+ transients in intact ventricular myocytes and on force-Ca2+
relationship of skinned ventricular muscle strips isolated from Mybpc3-targeted knock-
in (KI) and wild-type (WT) mice. Fractional sarcomere shortening and Ca2+ transients
were analyzed at 37◦C under 1-Hz pacing in the absence or presence of EGCg
(1.8µM). At baseline and in the absence of Fura-2, KI cardiomyocytes displayed lower
diastolic sarcomere length, higher fractional sarcomere shortening, longer time to peak
shortening and time to 50% relengthening than WT cardiomyocytes. In WT and KI
neither diastolic sarcomere length nor fractional sarcomere shortening were influenced by
EGCg treatment, but relaxation time was reduced, to a greater extent in KI cells. EGCg
shortened time to peak Ca2+ and Ca2+ transient decay in Fura-2-loaded WT and KI
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cardiomyocytes. EGCg did not influence phosphorylation of phospholamban. In skinned
cardiac muscle strips, EGCg (30µM) decreased Ca2+ sensitivity in both groups.
Conclusion: EGCg hastened relaxation and Ca2+ transient decay to a larger extent in
KI than in WT cardiomyocytes. This effect could be partially explained by myofilament
Ca2+ desensitization.
Keywords: epigallocatechin-3-gallate, hypertrophic cardiomyopathy, Mybpc3, myofilament Ca2+ sensitivity,
relaxation, Ca2+ transient
INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most common
cardiac genetic disease, with more than 1400 different mutations
in genes encoding primarily sarcomeric proteins (Friedrich and
Carrier, 2012; Maron et al., 2014; Ho et al., 2015). The most
frequently mutated genes are MYH7 (encoding β-myosin-heavy
chain) and MYBPC3 (encoding cardiac myosin-binding protein
C), which constitute about 80% of known mutations. Besides a
typical hypertrophy of the left ventricle, patients often present
a normal or increased ejection fraction, but a compromised
diastolic function with an incomplete relaxation and increased
filling pressures (Elliott et al., 2014). Diastolic dysfunction
may result in left atrial enlargement and is associated with
exercise intolerance and bad prognosis in HCM, primarily due to
supraventricular arrhythmias (Yang et al., 2009). Tissue Doppler
measurements have revealed that a reduction in systolic and
diastolic velocities is prominent even before the development of
left ventricular hypertrophy (Charron et al., 1997).
Increased myofilament Ca2+ sensitivity, as observed in three
Mybpc3 cardiomyopathy mouse models (Mybpc3 KO and KI)
developed by us and others (Cazorla et al., 2006; Pohlmann
et al., 2007; Vignier et al., 2009; Fraysse et al., 2012; Barefield
et al., 2014), and in other animal models of HCM (Knollmann
et al., 2001; Robinson et al., 2007; Iorga et al., 2008), could be an
underlying cause of diastolic dysfunction. This observation has
also been made in human HCM samples (Jacques et al., 2008;
van Dijk et al., 2009, 2012) and could explain the incomplete
relaxation in diastole inMYBPC3-associatedHCM (and probably
other cases associated with an increased Ca2+ sensitivity).
Additionally, myofilaments with increased sensitivity to Ca2+
may act as Ca2+ buffers, prolonging the export of Ca2+ and
relaxation time which could contribute to diastolic dysfunction
and arrhythmias (Morimoto et al., 1998; Baudenbacher et al.,
2008). These findings support the hypothesis that interventions
decreasing myofilament Ca2+ sensitivity could reverse the
phenotype of HCM and have therapeutic value (Jagatheesan et al.,
2007; Alves et al., 2014; Tardiff et al., 2015).
Epigallocatechin-3-gallate (EGCg), a major component
of green tea, has been suggested to be effective against
cardiovascular diseases. Proposed mechanisms were anti-
oxidative, anti-inflammatory, vasorelaxant, and positive
inotropic effects (Chyu et al., 2004; Lorenz et al., 2004; Ludwig
et al., 2004). Furthermore, it was shown that EGCg lowered
myofilament Ca2+ sensitivity in a transgenic HCMmouse model
expressing a human cardiac troponin T (TNNT2, cTnT) mutant
(Tadano et al., 2010) and in HCM-associated human cardiac
troponin I (TNNI3, cTnI) and cTnT mutants in a reconstituted
acto-myosin system (Warren et al., 2015; Messer et al., 2016).
However, the effects of EGCg were not evaluated in other HCM
models associated with mutations in the thick filament of the
sarcomere. SinceMYBPC3 is the major disease gene constituting
45% of genetically diagnosed HCM cases (Ho et al., 2015), we
used a representative mouse model carrying the human c.772G>
A MYBPC3 mutation (Vignier et al., 2009). This mutation
was found in 14% unrelated HCM patients in Tuscany and is
associated with a bad prognosis (Richard et al., 2003; Girolami
et al., 2006; Ho et al., 2015). These mice exhibit, in addition
to left ventricular hypertrophy and decreased fractional area
shortening, increased myofilament Ca2+ sensitivity, and diastolic
dysfunction (Fraysse et al., 2012). We evaluated the acute effects
of EGCg on sarcomere shortening and Ca2+ transient in intact
ventricular myocytes and on force-Ca2+ relationship of skinned
cardiac muscle strips isolated from KI and wild-type (WT) mice.
MATERIALS AND METHODS
Animals
TheMybpc3 KI cardiomyopathy mouse model was generated by
the targeted insertion of a G > A transition on the last nucleotide
of exon 6 and maintained on the Black Swiss background
(Vignier et al., 2009; Fraysse et al., 2012; Schlossarek et al.,
2012, 2014; Gedicke-Hornung et al., 2013; Mearini et al., 2013,
2014; Stöhr et al., 2013; Friedrich et al., 2014; Najafi et al., 2015;
Thottakara et al., 2015; Flenner et al., 2016). This study was
carried out in accordance with the recommendations of the guide
for the care and use of laboratory animals published by the
NIH (Publication No. 85–23, revised 2011 published by National
Research Council). All experimental procedures were in harmony
with the German Law for the Protection of Animals and the
protocol was approved by the Ministry of Science and Public
Health of the City State of Hamburg, Germany (Org 653).
Ventricular Myocyte Preparation
Cardiomyocytes were isolated from WT and KI mouse heart
ventricles as previously described (El-Armouche et al., 2007;
Pohlmann et al., 2007; Flenner et al., 2016). Mice were
anesthetized with CO2 and sacrificed by cervical dislocation.
Hearts were excised, cannulated via the aorta and installed
on a temperature-controlled (37◦C) perfusion system. After
retrograde perfusion with Ca2+-free buffer solution (113mM
NaCl, 4.7mM KCl, 0.6mM KH2PO4, 0.6mM Na2HPO4,
1.2mM MgSO4, 12mM NaHCO3, 10mM KHCO3, 30mM
taurine, 5.55mM glucose, 10mM 2,3-butanedione monoxime
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10mM HEPES, pH 7.46) for 6.5min, hearts were digested
with 0.075mg/ml Liberase TM (Roche Diagnostics, Mannheim,
Germany) dissolved in buffer solution containing 12.5µM
CaCl2 for 7–8min. Ventricles were disconnected from the atria
and minced with forceps to dissociate single cardiomyocytes.
Afterwards Ca2+ was introduced stepwise up to a concentration
of 1mM.
Sarcomere Shortening and Ca2+ Transient
Measurements in Intact Ventricular
Myocytes
For contractile analysis only rod-shaped myocytes without
membrane blebs, hypercontractile zones, and spontaneous
activity showing a stable contraction amplitude and rhythm
at 1-Hz pacing frequency (4ms long 10V pulses) and 37◦C
were recorded. Sarcomere shortening and Ca2+ transients were
recorded using a video-based sarcomere detection system and
analyzed with the appendant software (IonWizard; IonOptix;
Milton, MA) as described (Flenner et al., 2016). For Ca2+
recordings, cells were loaded with 0.6µM Fura-2-AM and
excited at 340 and 380 nm while the emitted light at 510 nm
was recorded with a photon multiplier tube. Measurements
of contraction and Ca2+ transients were first performed by
perfusion of the cells in basal buffer (135mMNaCl, 4.7mM KCl,
0.6mM KH2PO4, 0.6mM Na2HPO4, 1.2mM MgSO4, 1.5mM
CaCl2, 20mM glucose, 10mM HEPES, pH 7.46). When the cells
showed stable contraction amplitude, contractile function was
recorded. Subsequently, the perfusion was switched to buffer
containing different EGCg concentrations (Sigma-Aldrich, 10
nM, 100 nM, 1µM, 1.8µM, 3µM, 10µM, 30µM, 100µM
for the concentration-response curve; 1.8µM for the definite
measurements in KI and WT cells) and contractile function was
recorded again.
Skinned Ventricular Trabeculae Force
Measurements
For the determination of force-Ca2+ relationships, trabeculae
were prepared from the left ventricular endocardial surface of
WT and KI mice as reported before (Flenner et al., 2016).
The Ca2+-sensitivity of skinned EHT strips was evaluated using
a permeabilized fiber test system (1400A; Aurora Scientific).
Triton X-100 permeabilized strips of the left ventricle of WT
and KI mouse hearts were mounted between a force transducer
and a length controller. Trabeculae were stretched above slack
length until they developed force in activating solution (pCa 4.5)
at 15◦C. Subsequently they were exposed to increasing Ca2+
concentrations from pCa 9 to pCa 4.5 in EGTA-buffer. Force
development was measured in each pCa solution. Measurements
were repeated in the presence of 30 µM EGCg after 5min
preincubation in relaxing solution (Flenner et al., 2016). In
every second measurement, EGCg was tested first and a control
measurement was performed 5 min after EGCg washout to
exclude time-dependent loss of force. Data were analyzed using
the Hill equation (Hill et al., 1980), with pCa50 as the free
Ca2+ concentration which yields 50% of the maximal force and
nH representing the Hill coefficient. The pCa50 represents the
measure of myofilament Ca2+ sensitivity.
Statistical Analysis
Data were expressed as mean±SEM. Comparisons were
performed by paired or unpaired Student’s t-test (effects in
intact cardiomyocytes in the absence or presence of EGCg),
and with one-way ANOVA, followed by Bonferroni’s post-test
as indicated in the figure legends (analysis of total, Ser16- and
Thr17 phosphorylated phospholamban levels in isolated cells),
as indicated in the figure legends. Concentration response
curves were fitted to the data points and force-pCa relationship
comparison was done by using extra sum-of-squares F-test
(GraphPad, Prism 6). A value of P < 0.05 was considered
statistically significant.
RESULTS
EGCg (1.8 µM) has no Effect on Diastolic
Sarcomere Length, But Shortens
Relaxation Time in Isolated
Cardiomyocytes
EGCg has been reported to concentration-dependently increase
contractile function in rodents’ cardiac myocytes and hearts
(Lorenz et al., 2008; Tadano et al., 2010). HCM patients
typically present with a normal or increased ejection fraction,
but a diminished diastolic function and incomplete relaxation
(Elliott et al., 2014). This is mimicked in cardiac myocytes
from Mybpc3 KI mice, which showed lower diastolic sarcomere
length and higher twitch amplitude than WT cardiomyocytes
(Fraysse et al., 2012). We aimed at using an EGCG concentration
that would not increase contraction amplitude. Therefore, we
performed paired concentration-response curves with sarcomere
shortening as the readout on isolated cardiac myocytes
of Mybpc3 WT mice with increasing EGCg concentrations
ranging from 10−8 to 10−4 M (Figure 1A). EGCg increased
sarcomere shortening in a concentration-dependent manner
(curve fit r2 = 0.85). The positive inotropic effect of EGCg
occurred within 5 min of exposure and was reversible by
washout (loss of effect after 5min). The highest concentration
of EGCg that did not alter myocyte contractions was 1.8
µM (=10−5.74M; Figures 1A,B), while EGCg concentrations
above ≥3µM (=10−5.52M) increased sarcomere shortening
(Figures 1A,C).
We therefore tested the acute effects of 1.8µM on
isolated cardiac WT and KI myocytes. At baseline and
in the absence of Fura-2, KI cardiomyocytes exhibited
lower diastolic sarcomere length and longer contraction
and relaxation times than WT (Figure 2), recapitulating a
relaxation deficit seen in human patients. Application of 1.8µM
EGCg did not affect fractional sarcomere shortening and
contraction time (Figures 2B,C). It did not further decrease
the pathological diastolic sarcomere length (Figure 2D) but
accelerated relaxation, i.e., it lowered relaxation time in both
genotypes (Figure 2E). This effect was stronger in KI cells
(Figure 2F).
Frontiers in Physiology | www.frontiersin.org 3 December 2016 | Volume 7 | Article 607
Friedrich et al. EGCg Accelerates Relaxation in HCM-Cardiomyocytes
FIGURE 1 | EGCg effect on Mybpc3WT cardiac myocyte contractility. (A) After isolation of ventricular myocytes from adult Mybpc3 WT mice, paired
(before/after EGCg) concentration-response curves were performed. Graph depicts % of fractional sarcomere shortening as readout with increasing EGCg
concentrations (10−8 = 100 nM, 10−7 = 10 nM, 10−6 = 1µM, 10−5.74 = 1.8µM, 10−5.52 = 3µM, 10−5 = 10µM, 10−4.52 = 30µM, 10−4 = 100µM; n =
3–9/concentration. Concentrations above ≥3µM EGCg caused a significant increase in sarcomere shortening. (B,C) Representative contractions of a cardiac
myocyte at baseline conditions (left) and after 5 min of exposure to 1.8 (B, right) or 30µM EGCg (C, right).
EGCg (1.8 µM) Increases Diastolic Ca2+
and Accelerates Ca2+ Transient Kinetics in
Isolated Cardiomyocytes
We then investigated whether EGCg influences Ca2+
homeostasis and performed Ca2+ transient analysis using
Fura-2 AM. Contractile parameters of Fura-2-loaded cells were
also measured and evaluated, but not represented here, as Fura-2
has a substantial Ca2+ buffering effect and therefore interferes
with contractile processes. At baseline, KI cardiomyocytes
exhibited no difference in Ca2+ peak height, diastolic Ca2+,
time to peak Ca2+, and time to 50% Ca2+ decay compared to
WT cells (Figure 3). Stimulation with EGCg had no influence
on Ca2+ peak height, but slightly increased diastolic Ca2+, and
markedly reduced time to peak Ca2+ and time to 50% Ca2+
decay in both groups. Even though the time to 50% Ca2+ decay
was longer in KI cells in the presence of EGCg, the delta was not
different to WT (WT −0.05 ± 0.008 s vs. KI −0.04 ± 0.0098 s,
P = 0.33, Student’s t-test). Plotting the sarcomere length against
the F340/380 ratio of Fura-2 in WT cells showed that with
1.8µM EGCg, the descending phase of the relation between
the F340/380 ratio and the sarcomere length was shifted to the
right, and the relaxed state of the sarcomere length in diastole
was reached at higher F340/380 ratios, resulting in smaller loops
(Figure 3F). Opposite results, a left-shift of the loop, had been
Frontiers in Physiology | www.frontiersin.org 4 December 2016 | Volume 7 | Article 607
Friedrich et al. EGCg Accelerates Relaxation in HCM-Cardiomyocytes
FIGURE 2 | Contractile parameters of Mybpc3WT and KI cardiomyocytes before and after treatment with EGCg. After isolation of ventricular myocytes
from adult Mybpc3 WT and KI mice, paired (before/after EGCg) measurements of contractile function were exerted. (A) Averaged sarcomere shortening traces of
Mybpc3 WT (black) and KI (red) cells in baseline and with EGCg. (B) Fractional sarcomere shortening, (C) contraction time (time from stimulation to peak of
contraction), (D) diastolic sarcomere length, and (E) relaxation time (time from peak of contraction to 50% relaxation) were analyzed. (F) Delta of relaxation time
(before/after EGCg). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. WT in the same condition, unpaired Student‘s t-test; #P < 0.05 vs. baseline, paired Student‘s t-test,
n = 17–22, N = 5.
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FIGURE 3 | Ca2+ transients and kinetics of Mybpc3WT and KI cardiomyocytes before and after treatment with EGCg. After isolation of cardiac myocytes
from adult Mybpc3 WT and KI mice, paired (before/after EGCg) measurements of Ca2+ transients were performed in Fura-2 loaded cells. (A) Averaged Ca2+
transients of Mybpc3 WT and KI cells in baseline and with EGCg. (B) Ca2+ peak height, (C) time to peak Ca2+ (from stimulation to peak of 340/380 ratio), (D)
diastolic Ca2+, and (E) time to 50% Ca2+ decay (from peak of 340/380 ratio to 50% decay) were analyzed. (F) Sarcomere length of Mybpc3 WT cells plotted against
the Fura-2 signal ratio F340/380 indicating the Ca2+ transient in the absence (black loop) or presence (dotted black loop) of 1.8µM EGCg, respectively. Loops
proceed in a counter-clockwise direction. **P < 0.01 vs. WT in the same condition, unpaired Student‘s t-test; #P < 0.05, ##P < 0.01 and ###P < 0.001 vs.
baseline, paired Student‘s t-test, n = 20–26, N = 5. For loops: n = 9.
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reported with the Ca2+ sensitizer CGP-48506 (Wolska et al.,
1996).
EGCg (30 µM) Decreases Myofilament
Ca2+ Sensitivity to a Greater Extent in KI
than in WT Skinned Ventricular Trabeculae
EGCg has been reported to decrease myofilament Ca2+
sensitivity in three HCM models expressing either a TNNT2
or TNNI3 mutation (Tadano et al., 2010; Warren et al., 2015;
Messer et al., 2016). To assess whether the EGCg effects in intact
cells resulted from a decrease in myofilament Ca2+ sensitivity,
we measured force-pCa relationships in skinned ventricular
trabeculae from WT and KI mice. At baseline and as observed
before (Fraysse et al., 2012; Flenner et al., 2016), skinned KI
trabeculae showed a higher pCa50thanWT trabeculae, indicating
higher myofilament Ca2+ sensitivity (Figures 4A–C). We first
tested a concentration of 10µM onMybpc3 KI muscle strips but
did not observe any effect (data not shown). Since other groups
had reported that EGCg concentrations below 30µM had no
effect on Ca2+ sensitivity we also used 30µM(Tadano et al., 2010;
Robinson et al., 2016). Incubation with 30µM EGCg shifted the
force-Ca2+ relationship to the right resulting in a lower pCa50
in both genotypes (Figures 4A–C), which indicates myofilament
Ca2+ desensitization. As observed in the myocyte experiments,
the effect of EGCg was stronger in skinned KI than WT muscle
strips (Figure 4D). The nHill coefficient did not differ between
the genotypes neither with nor without EGCg (Figure 4E).
DISCUSSION
One major feature of HCM is a compromised diastolic function
with an incomplete relaxation (Elliott et al., 2014). Increased
myofilament Ca2+ sensitivity as seen in HCM patients and in
several mouse models of HCM (Morimoto et al., 1998; Robinson
et al., 2007; Huke and Knollmann, 2010; Kimura, 2010; Fraysse
et al., 2012; Moore et al., 2012; van Dijk et al., 2012; Barefield
et al., 2014; Flenner et al., 2016) could contribute to diastolic
dysfunction. Recent findings advocate a potential therapeutic role
for EGCg in HCM since it lowered the increased myofilament
Ca2+ sensitivity in a transgenic HCM mouse model expressing
a human cardiac troponin T (TNNT2, cTnT) mutant (Tadano
et al., 2010) and in HCM-associated human cardiac troponin I
(TNNI3, cTnI) and cTnT mutants in a reconstituted acto-myosin
system (Warren et al., 2015; Messer et al., 2016). The aim of
this study was to evaluate whether EGCg has beneficial effects
in another thick filament model of HCM, carrying a human
mutation in the thick filament protein gene MYBPC3. The main
findings of this study were: 1. At baseline and in the absence of
Fura-2, KI cardiomyocytes exhibited higher fractional sarcomere
shortening, lower diastolic sarcomere length, longer contraction
and relaxation times than WT cells, without differences in
Ca2+ transient amplitude and kinetics. 2. EGCg had no effect
on sarcomere shortening or diastolic sarcomere length, but
it accelerated relaxation and Ca2+ transient decay in Mybpc3
WT and KI cardiomyocytes. 3. EGCg induced myofilament
Ca2+ desensitization in permeabilized left ventricular trabeculae
isolated from Mybpc3 WT and KI mouse hearts. 4. EGCg effects
on relaxation time and myofilament Ca2+ sensitivity were more
pronounced in KI cells and muscle strips, respectively.
EGCg is a major component of green tea and has been
reported to have beneficial effects in a variety of diseases (Peng
et al., 2011; Brückner et al., 2012; Ortsäter et al., 2012). Suggested
mechanisms in the context of cardiovascular diseases are anti-
oxidative, anti-inflammatory, vasorelaxant and positive inotropic
effects (Chyu et al., 2004; Lorenz et al., 2004; Ludwig et al.,
2004). Since HCM patients typically present with a normal
or even increased ejection fraction, but with a diminished
diastolic function (Elliott et al., 2014), mimicked in Mybpc3 KI
mice (Fraysse et al., 2012), we intended to apply the highest
concentration that would not increase sarcomere shortening
(1.8µM) to evaluate its effects on the impaired relaxation in KI
myocytes. Similar to Lorenz et al. and Tadano et al. (Lorenz et al.,
2008; Tadano et al., 2010), who reported a positive inotropic
effect between 2.5 and 5µM in mouse hearts and rat myocytes,
we observed an increase in fractional sarcomere shortening at
concentrations above 3µM. Although we observed no effect on
diastolic sarcomere length in WT cells at 1.8µM EGCg, we
speculated that this concentration could have an effect in KI
cells. This was not the case. Nevertheless, 1.8µM EGCg reduced
relaxation time, and this effect was more prominent in KI cells,
whereas the effects on diastolic Ca2+ and Ca2+ kinetics did not
differ between the genotypes. The increase in diastolic Ca2+
could be explained by an inhibiting effect on the Na+/Ca2+
exchanger (NCX), as reported with 10 nM (Feng et al., 2012)
and 2.5µM (Lorenz et al., 2008). The faster time to peak Ca2+ is
probably due to EGCg effects on the ryanodine receptor. Indeed,
it has been shown that EGCg activates the ryanodine receptor
at 10 nM in sarcoplasmic reticulum (SR) vesicles isolated from
rabbit left ventricles (Feng et al., 2012) and in the range of 1
nM–20µM in junctional SR vesicles isolated from skeletal muscle
(Najafi et al., 2015). At a concentration of 1.8µM, EGCg had
no effect on PLB Ser16/Thr17 phosphorylation (Supplemental
Figure 1). This supports findings of Lorenz et al., who neither
observed an effect on PLB Ser16/Thr17 phosphorylation with
EGCg (4µM) nor an influence on EGCg actions on contractility
after β1-adrenoceptor inhibition with 3µM metoprolol (Lorenz
et al., 2008). We thus exclude that the acceleration of relaxation
and Ca2+ kinetics are mediated via the β1-adrenergic pathway.
In contrast to Lorenz et al. we did not observe an increased
Ca2+ peak height in the presence of 1.8µM EGCg (Lorenz
et al., 2008). We therefore assume that at this concentration
EGCg does not increase sarcoplasmic reticulum (SR) Ca2+ load.
Data from canine SR vesicles and HEK293 cell microsomes
show that EGCg concentrations > 4.8µM directly inhibit SR
calcium ATPase (Kargacin et al., 2011). Additionally, Feng et al.
reported no effect on SERCA in rabbit cardiac and skeletal SR
membranes with 1–2µM EGCg (Feng et al., 2012; Najafi et al.,
2015). We therefore rule out that the acceleration of relaxation
kinetics in the presence of 1.8µM EGCg is due to an increased
SERCA activity. A plausible contributing reason could be an
EGCg-mediated decrease in myofilament Ca2+ sensitivity.
Indeed, it has been reported that EGCg lowered the increased
myofilament Ca2+ sensitivity and improved the diastolic
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FIGURE 4 | Force-Ca2+ relationship of permeabilized cardiac muscle strips of WT and KI mice before and after treatment with 30µM EGCg.
Force-Ca2+ concentration in (A) WT strips, (B) KI strips. (C) The pCa50 represents the measure of myofilament Ca
2+-sensitivity. (D) Delta of pCa50before and after
EGCg. (E) nHill coefficient±EGCg. **P < 0.01 and ***P < 0.001 vs. WT in the same condition, unpaired Student‘s t-test; ##P < 0.001 and ###P < 0.001 vs.
baseline, paired Student‘s t-test, concentration response curves were fitted to the data points and curve comparison was done by using extra sum-of-squares F-test;
n = 10; N = 6 mice/genotype.
function of isolated working heart preparations from a transgenic
HCM mouse model expressing a human TNNT2 mutation
(Tadano et al., 2010). EGCg also restored the increased Ca2+
sensitivity of HCM-associated human cTnI and cTnT mutants
in a reconstituted acto-myosin system (Warren et al., 2015;
Messer et al., 2016). Similar to these previous data, 30 µM
EGCg decreased Ca2+ sensitivity in our thick myofilament
mouse model that carries a frequent HCM mutation in the
most frequently mutated gene (Vignier et al., 2009; Fraysse
et al., 2012; Ho et al., 2015). It has been suggested that EGCg
binding to the C-terminal region of cardiac troponin C (cTnC)
alters the interaction between cTnC and cTnI and therefore
the sensitivity of the myofilaments to Ca2+ (Liou et al., 2008;
Robertson et al., 2009). In both intact myocytes and skinned
trabeculae, EGCg had a more profound effect on cells and
strips of the KI genotype. This could also be related to the
longer baseline relaxation time and elevated myofilament Ca2+
sensitivity in KI mice. This is similar to a recent study in
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which we showed that the myofilament Ca2+-desensitizing effect
of ranolazine was only present in KI, but not in WT muscle
strips (Flenner et al., 2016). Since EGCg is not a pure Ca2+
desensitizer (Stangl et al., 2007), side effects such as arrhythmias
or blood pressure lowering reported in in vivo applications would
also be expected in WT mice (Alvarez et al., 2006; Bao et al.,
2015).
The study has two limitations. (1) The Mybpc3 KI model
shows many HCM features only at the homozygous state.
Additionally, Mybpc3 KI mice present a reduced ejection
fraction. These two points are in contrast to the more
common findings in HCM patients who present left ventricular
hypertrophy, interstitial fibrosis, and diastolic dysfunction with
heterozygous mutation states and normal or even supra-normal
ejection fraction. (2) The Ca2+-desensitizing effect of EGCg
on the permeabilized trabeculae was only detected at 30µM,
which is higher than the concentrations used in the intact
myocyte experiments. This discrepancy has also been observed
before (Tadano et al., 2010; Robinson et al., 2016). It should be
kept in mind that in permeabilized cardiac muscle fibers the
effective concentrations of the Ca2+-sensitizers pimobendan and
EMD57033 were also reported to be much higher than those
estimated in vivo (Fujino et al., 1988; Solaro et al., 1993; Chu
et al., 1999), proposing that drugs could have lower potency in
permeabilized cardiac muscle preparations than in vivo, since
important components enhancing drug uptake or function such
as membrane transporters or the SR could be disturbed in their
function or missing after muscle strip skinning.
CONCLUSION
EGCg accelerated relaxation and Ca2+ transient decay inMybpc3
WT and KI cardiomyocytes, which seems to be partly due to
Ca2+ desensitization of the myofilaments. We show for the first
time that EGCg is also effective in a thick filament mutation
mouse model. In support of other studies (Tadano et al., 2010;
Warren et al., 2015; Messer et al., 2016), this confirms that
EGCg belongs to a new class of Ca2+ antagonists which have
a very favorable functional profile acting directly on the Ca2+
regulatory system of cTnC. Further efforts should be made
to develop a new generation of Ca2+ desensitizers based on
the green tea catechin EGCg with even more potency and
specificity to avoid potential side effects such as arrhythmias
or lowering of blood pressure that could also affect healthy
individuals.
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